scispace - formally typeset
O

Olga Yuzhakov

Publications -  8
Citations -  1374

Olga Yuzhakov is an academic researcher. The author has contributed to research in topics: Antigen & Immunogenicity. The author has an hindex of 6, co-authored 6 publications receiving 737 citations.

Papers
More filters
Journal ArticleDOI

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.

TL;DR: These data show that LNP-formulated, modified mRNA vaccines can induce protective immunogenicity with acceptable tolerability profiles, demonstrating robust prophylactic immunity in humans.
Journal ArticleDOI

Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines

TL;DR: Screening a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model shows that mRNA vaccine tolerability can be improved without affecting potency.
Journal ArticleDOI

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

TL;DR: It is shown that modified non-replicating mRNA encoding influenza H10 hemagglutinin and encapsulated in lipid nanoparticles (LNP) induce protective HA inhibition titers and H10-specific CD4+ T cell responses after intramuscular or intradermal delivery in rhesus macaques.
Journal ArticleDOI

Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

TL;DR: It is demonstrated that the immunization of mice and nonhuman primates with lipid nanoparticles encapsulating modified mRNA encoding CMV glycoproteins gB and pentameric complex (PC) elicit potent and durable neutralizing antibody titers.
Journal ArticleDOI

Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells.

TL;DR: It is demonstrated that modified non-replicating mRNA encoding influenza H10 encapsulated in lipid nanoparticles (LNP) in non-human primates potently induce an immunological repertoire associated with the generation of high magnitude and quality antibodies.